Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seattle Genetics Diversifies Beyond ADCs With Cascadian Acquisition

Executive Summary

The biotech already was looking to move into solid tumors, particularly breast cancer, with its antibody-drug conjugates, but now will take over a promising oral candidate in pivotal studies in HER2-positive breast cancer.


Related Content

Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising
ECHELON-2 Ushers In Another New Adcetris Indication For Seattle Genetics
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples
Oncothyreon reports another tecemotide failure
Stimuvax failure dents Merck Serono but freshens Oncothyreon


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts